Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion

Scand J Gastroenterol. 1995 Sep;30(9):872-5. doi: 10.3109/00365529509101593.

Abstract

Background: The non-bleeding visible vessel in a peptic ulcer is the highest risk factor for a bleeding recurrence among not actively bleeding lesions. Perendoscopic injection of sclerosing compounds is usually used as prophylaxis against rebleeding.

Methods: Forty-two patients with visible vessels in a peptic ulcer at an emergency endoscopic procedure have been studied: 21 patients underwent prophylactic perendoscopic hemostasis, and 21 patients were infused with omeprazole intravenously.

Results: Eight patients (19%), four in each group, had early rebleedings (within 48 h after the enrollment). There was no significant difference between the two types of treatment. At the endoscopic control after 48 h there were significantly more lesions with higher risk of rebleeding (Forrest IIa and IIb) in the group treated with perendoscopic hemostasis.

Conclusions: Our data suggest that omeprazole infusion is a valid alternative to injection treatment of non-bleeding visible vessels.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Anti-Ulcer Agents / administration & dosage*
  • Anti-Ulcer Agents / therapeutic use
  • Chi-Square Distribution
  • Female
  • Gastroscopy
  • Hemostasis, Endoscopic*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Omeprazole / administration & dosage*
  • Omeprazole / therapeutic use
  • Peptic Ulcer Hemorrhage / diagnosis
  • Peptic Ulcer Hemorrhage / prevention & control
  • Peptic Ulcer Hemorrhage / therapy*
  • Stomach Ulcer / complications*
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Omeprazole